Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03751007
Recruitment Status : Recruiting
First Posted : November 22, 2018
Last Update Posted : June 6, 2019
Sponsor:
Collaborators:
ActoBio Therapeutics
TFS Trial Form Support
Information provided by (Responsible Party):
Intrexon T1D Partners, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 31, 2019
  Estimated Study Completion Date : June 30, 2020